Filing Flows › Comparisons › GILD vs BIIB
Gilead Sciences vs Biogen: GILD and BIIB compared
Gilead Sciences is the larger company: $8.3B of revenue in its latest quarter (Q3 2026) against $2.8B for Biogen (Q3 2026). Biogen is growing faster (+11% against +7% a year earlier). Gilead Sciences is more profitable, with an operating margin of 41.7% against -0.3%.
Where the money goes: GILD and BIIB
Gilead Sciences (GILD) · Q3 2026
Gilead Sciences, Q3 2026: revenue $8.3B (+7% year over year), operating margin 41.7%, net earnings $2.4B, operating cash flow $5.0B. The chart follows the revenue to costs, profit and cash.
Biogen (BIIB) · Q3 2026
Biogen, Q3 2026: revenue $2.8B (+11% year over year), operating margin -0.3%, net loss $20.6M, operating cash flow $641M. The chart follows the revenue to costs, profit and cash.
| Gilead Sciences (GILD) | Biogen (BIIB) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $8.3B | $2.8B |
| Revenue growth, Y/Y | +7% | +11% |
| Operating margin | 41.7% | -0.3% |
| Net earnings | $2.4B | −$20.6M |
| Net margin | 29.3% | -0.7% |
| Operating cash flow | $5.0B | $641M |
| Free cash flow | $4.8B | $600M |
| Market value | $209.6B | $36.7B |
| P/E | — | 107.0× |
| Analysts’ mean target | $174.77 | $266.38 |
Where the revenue comes from
Gilead Sciences
- Total HIV: $6.3B (76%)
- Trodelvy: $506M (6%)
- Total Cell Therapy: $355M (4%)
- Genvoya: $339M (4%)
Biogen
- MS Product Revenues: $919M (33%)
- Rare Disease Product Revenue: $676M (24%)
- SPINRAZA: $461M (16%)
- Royalty Attributed to OCREVUS: $370M (13%)
Questions
Which is bigger, Gilead Sciences or Biogen?
Gilead Sciences is the larger company: $8.3B of revenue in its latest quarter (Q3 2026) against $2.8B for Biogen (Q3 2026).
Is Gilead Sciences or Biogen growing faster?
Biogen is growing faster (+11% against +7% a year earlier).
Which is more profitable, Gilead Sciences or Biogen?
Gilead Sciences is more profitable, with an operating margin of 41.7% against -0.3%.
More: Gilead Sciences earnings · how Gilead Sciences makes money · Biogen earnings · how Biogen makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 30, 2026; 10-Q filed Oct 28, 2026). Fiscal quarters can end on different dates. Not investment advice.